Magazine Article | August 2, 2021

IPO, M&A, And SPAC — 3 Life Science Execs Recount Going Public

Source: Life Science Leader

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

Had I said biotech IPOs were hot last year, it could be construed as one of the biggest understatements of all time, as 2020 biotech IPOs shattered all records. Further, the trend seems to be continuing for 2021. Taking a company public may not be every entrepreneur’s dream, but it is for many life sciences companies, as large amounts of capital remain necessary to bring new therapeutics to market. And as 2020 seems to have forever changed how IPOs (and going public) are done, it seems like there is a great opportunity to capture some wisdom from those who have been there, done that.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader